A combination treatment regimen of CRESTORTM (rosuvastatin) 40 mg and ezetimibe 10 mg achieved an unprecedented 70 per cent reduction in LDL-C which is the largest reduction in LDL-C ever seen in a statin clinical trial. In just six weeks, this combination treatment also helped more high-risk patients (94 per cent) - whose LDL-C needs to be reduced to less than 100mg/dL- achieve their guideline LDL-C goals than those treated with CRESTOR alone (79 per cent ) (p

Tag Cloud